Is Constipation Common with Gliomas?
Constipation is not a characteristic or commonly reported symptom directly caused by gliomas themselves. While constipation is extremely common in advanced cancer patients generally (40-90% prevalence), the available evidence does not identify it as a typical presenting symptom or direct consequence of glioma tumors 1.
Understanding the Context
The distinction here is critical: gliomas present with neurological symptoms related to their location in the brain, not gastrointestinal symptoms. The characteristic presentations of gliomas include 2:
- New-onset epilepsy
- Focal neurological deficits (pareses, sensory disturbances)
- Neurocognitive impairment
- Signs of increased intracranial pressure
Recent comprehensive symptom network analyses in glioma patients identified core symptom clusters including motor symptoms, fatigue, pain, and a gastrointestinal/seizures/bladder control cluster 3, 4. However, even within the gastrointestinal cluster, constipation was not highlighted as a predominant or core symptom.
When Constipation Does Occur in Glioma Patients
Constipation in glioma patients is typically secondary to treatment or supportive care medications, not the tumor itself 1. The most important causes include:
Primary Contributors:
- Opioid analgesics for pain management (opioid-induced constipation affects most patients on these medications)
- Reduced mobility from neurological deficits
- Anticonvulsant medications for seizure control
- Corticosteroids (dexamethasone) commonly used for cerebral edema
- Chemotherapy agents (particularly vinca alkaloids, platinum compounds)
Important Caveat:
While neurological diseases can cause constipation through disruption of autonomic nervous system function 5, gliomas would need to affect specific brain regions controlling bowel function (rare) or cause severe global neurological impairment to directly cause constipation.
Clinical Implications
If a glioma patient develops constipation, actively investigate medication-related causes first, particularly opioid use, rather than attributing it to tumor progression. The ESMO guidelines emphasize that constipation in cancer patients is "poorly recognized and poorly treated" despite causing significant morbidity 1.
Proactive bowel management should be initiated when starting opioids or other constipating medications in glioma patients, as prevention is more effective than treatment of established constipation 1.